Full Press Release Details
Inc. Announces Pricing of $10 Million Underwritten Public Offering
Aviv, Israel- June 29, 2018 - InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems
(EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering
of 33,333,333 units at a price to the public of $0.30 per unit. InspireMD expects to receive aggregate gross proceeds of approximately
$10 million from the offering, assuming no exercise of the underwriter's option to purchase additional securities. Each
unit contains one share of common stock (or common stock equivalent) and one Series D warrant to purchase one share of common
stock. The common stock (or common stock equivalents) and the accompanying Series D warrants included in the units can only be
purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.
connection with the offering, InspireMD has granted the underwriter a 30-day option to purchase up to additional 4,999,999 shares
of common stock and/or Series D warrants to purchase up to 4,999,999 shares of common stock. The offering is expected to close
on or about July 3, 2018, subject to customary closing conditions.
Wainwright & Co. is acting as the sole book-running manager for the offering.
intends to use $2,264,269 of the proceeds of this offering to redeem the outstanding shares of its Series C Convertible Preferred
Stock held by the holder of its Series D Convertible Preferred Stock and all outstanding shares of its Series D Convertible Preferred
Stock and the remainder of the net proceeds of this offering for research and development, capital expenditures, working capital
and other general corporate purposes, as well as potential acquisition.
registration statement on Form S-1 relating to the public offering of the securities described above was filed with the Securities
and Exchange Commission ("SEC") and was declared effective on June 29, 2018. The offering is being made only by means
of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to and describing the
terms of the offering has been filed with the SEC and a final prospectus relating to the offering will be filed with the SEC,
and will be available on the SEC's website at www.sec.gov. Copies of the final prospectus, when available, may also be obtained
from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release includes statements relating to the offering of InspireMD's securities, including as to the closing of this
offering described above and the use of net proceeds therefrom. These statements and other statements in this press release constitute
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties
include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii)
negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for
the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v)
product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors
for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products,
(ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be
successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our
reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet
our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain (xiii) the
fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical
and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each
jurisdiction and (xiv) market conditions. More detailed information about the Company and the risk factors that may affect the
realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission
(SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes
no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.